Market Size of Trulicity Industry
| Study Period | 2021-2029 |
| Market Size (2024) | USD 8.60 Billion |
| Market Size (2029) | USD 14.20 Billion |
| CAGR (2024 - 2029) | > 10.00 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Trulicity Market Analysis
The Trulicity Market size is estimated at USD 8.60 billion in 2024, and is expected to reach USD 14.20 billion by 2029, growing at a CAGR of greater than 10% during the forecast period (2024-2029).
The Centers for Disease Control (CDC) determined that COVID-19 was a serious public health threat for people with serious chronic diseases, including diabetes. People with diabetes were more likely to experience complications when infected with the virus. As per the American Diabetes Association, people with diabetes, if uncontrolled, had worse outcomes if infected with a virus such as COVID-19. The International Diabetes Federation explained that when people with diabetes develop a viral infection, it can be harder to treat due to fluctuations in blood glucose levels and diabetes complications as the immune system is compromised, making it harder to fight the virus and likely leading to a longer recovery period.
Further, during the COVID-19 pandemic, many restrictions were imposed, putting people into lockdown, which led to contribution to obesity through unhealthy diets, physical inactivity, or highly sedentary behaviors. Further, these factors were associated with sustained weight gain and persisted even after lockdown restrictions were lifted. Weight management guidelines recommended a multi-component approach for weight loss in patients living with obesity and overweight. The use of anti-obesity medications was an effective option for weight control to improve the quality of life and prevent the progression of weight-related comorbidities.
Trulicity is an injectable diabetes medicine that helps control blood sugar levels. Trulicity is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is also used to help reduce the risk of serious heart problems such as heart attack or stroke in adults who have type-2 diabetes and heart disease. It is used for adults and children 10 years of age and older with type-2 diabetes, along with diet and exercise to improve blood sugar.
The World Health Assembly Resolution 2022 recommends the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increase in access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO to advise the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
Major factors that are expected to boost the growth of the studied market in the forecast period are rising obesity and inactivity rates among people, which have resulted in an increase in the diabetes population over time, a rise in the sedentary lifestyle, improper dietary patterns, and the inherent history of diabetes disorders. In addition, rising investment in research and development, technological developments, and new product launches will further provide potential opportunities for the growth of glucagon-like peptide 1 (GLP-1) agonists such as Trulicity in the coming years.
